In-depth trading ideas

Discover detailed market analysis from traders. See how others approach this instrument, compare different strategies, and discover perspectives that can shape your own view.

$DHR setting up nicely, calls look attractive I've started a position in NYSE:DHR , based on an inverted H&S observed on the daily/weekly timeframes. There's a gap to fill should price clear the $198 level on the daily chart. My chosen vehicle is DEC 2026 $210 CALLs, which should that gap fill deliver a roughly 70% return. I may chose to close only a portion of the position and hold longer for a second price target with a similar gap-fill objective. As for the broader setup, healthcare stocks AMEX:XLV have been outperforming NYSE:DHR looks like a laggard, so this could be a "catch-up trade" as well.

by quickshiftinn

$DHR - 50 SMA Breakout and Cup and Handle Pattern 💡 Swing setup idea 50 SMA breakout / Cup and handle formation 🔎 Analysis summary: The stock crossed above the 50 SMA and is currently forming a cup and handle pattern. We are also seeing rising, above-average buyers volume supporting the move. 👀 Levels to watch: Entry trigger: Break above $189.21 Target: $217.42 Stop: Under the breakout level Friendly reminder: Always keep an eye on the broader market conditions and overall trend, as they can heavily influence individual stock setups! 💬 What do you think of this setup? Let me know in the comments! 👇 Good luck! ⚠️ Note: This is for educational purposes only and is not financial advice.

$DHR - H&S bottom - End of Human Trials?For a head-and-shoulders bottom (inverse H&S) — a downtrend-reversal pattern — the classical Edwards & Magee volume rules go element by element, and the governing idea is that volume should contract into the successive lows and expand on the right-side advances. Volume confirmation matters more here than in the topping pattern, because a rally needs buying fuel to sustain it, whereas a top can roll over under its own weight. Left shoulder. The decline into the left-shoulder low is typically on heavy/climactic volume (it's still part of the active downtrend). Volume then recedes on the bounce up from that low. Head. The decline to the head — the lowest low — should occur on lighter volume than the left-shoulder decline. That diminishing volume on a lower low is the first tell of selling exhaustion. The rally off the head then shows a noticeable pickup in volume — the first sign of genuine demand/accumulation. Ideally this advance carries more volume than the advance off the left shoulder. Right shoulder. This is the hallmark: the decline into the right-shoulder low should be on the lightest volume of the three troughs — distinctly dry. Sellers are spent; the higher low can't attract supply. Volume then begins to expand again as price rallies back toward the neckline. Neckline breakout (the mandatory one). The upside break through the neckline must be accompanied by a marked surge in volume. This is not optional for a bottom — an inverse H&S that breaks out on weak volume is suspect and prone to failure. (Contrast the H&S top, where a valid breakdown can occur on quiet volume.) So the clean heuristic: volume should descend through left shoulder → head → right shoulder (lightest), while the advances on the right half of the pattern build, climaxing in a volume burst on the neckline break. A useful cross-check is comparing the left half (declines) against the right half (advances) — accumulation should be visibly shifting to the buy side. Two caveats worth keeping: these are idealized guidelines, not pass/fail gates at every point — real patterns are messier, and volume is probabilistic confirmation rather than a hard rule everywhere except the breakout, where the volume expansion is the one piece most technicians treat as non-negotiable. fundamentally, trading at 17.5x fwd ev/ebitda. w it's 5 year average at 22.22xev/ebitda. operationally, My read for an AI-themed expression If the goal is AI-discovery beneficiary, DHR is the more concentrated bet: bioprocessing is the chokepoint where discovered biologics must get manufactured, and the order inflection is real and current. TMO is the more diversified, lower-beta way to own the same theme, but you're paying a fuller multiple for slower organic growth and you carry more services/CDMO drag. What would have to be true for the bull case (either name): (1) the bioprocessing recovery is a multi-quarter cycle, not a one-print bounce; (2) pharma/biotech capex re-accelerates as funding constraints ease; (3) AI nets out as a volume tailwind (more molecules to make) rather than an efficiency headwind (fewer experiments per molecule) over the next decade. Lose #3 and the premium multiple on both is the thing that's actually at risk. is that the design-to-validation loop is closing the other way: in Q1 2026, a cluster of peer-reviewed papers reported AI-designed molecules that were experimentally validated in preclinical wet-lab settings, not just scored on test sets. Every in-silico design still has to survive contact with a bench, and AI is generating more candidates to validate, not fewer. So today the wheel turns in DHR/TMO's favor. But the terminal-value question — does AI eventually thin out the physical workflow? — is the unpriced risk, and it's exactly the kind of thing a 20-year DCF buries in the perpetuity assumption where no one looks. Bull case The bioprocessing cycle just inflected. Q1-26 equipment orders at Cytiva grew >30% YoY — the first positive result in nearly two years. After the 2023–24 "bioprocessing winter," that's the single most important leading indicator for the segment that drives ~40% of profit. Earnings are beating. Q1-26 adjusted EPS of $2.06 beat consensus of $1.94 by ~6% and grew 9.5% YoY, and they nudged FY26 guidance up to $8.35–8.55. Direct AI integration into the moat. Under a dedicated Chief Data & AI Officer, DHR is embedding AI into Cytiva ("Digital Bioprocessing") to optimize yields and shorten timelines, and using ML across Genedata (candidate screening) and IDT (CRISPR guide-RNA design). The AI strategy is process-led (DBS) — wet-lab-in-the-loop, not algorithm-for-its-own-sake. ~75–80% recurring revenue gives it the captive razor-blade economics that justify a premium multiple, and it's trading below its own history. My own DCF work last session put Danaher's bull case at ~$240 — and that's roughly where Morningstar's base sits. So the upside scenario is well-defined. Bear case The order pop is one quarter off a depressed base. +30% YoY laps the trough of the worst bioprocessing downturn in a decade. One green quarter is not a durable cycle, and equipment orders are the noisiest line in the P&L. Masimo integration + CFO transition = stacked execution risk. A long-time CFO departed Feb 2026 right as DHR digests a ~$9.9B EV deal that's testing the board's capital-allocation reputation. The "AI" is mostly yield-optimization software bolted onto a hardware business — nice for stickiness, not obviously a re-rating catalyst or a new revenue engine. From my model: the stock is only cheap if you accept Morningstar's 7.4% WACC and 36.6% margin ramp. At a defensible ~8.3% WACC and ~34% margins, base value is ~$147 — i.e., roughly fair-to-rich here, not a bargain.

by DillyDallyGally

Where is Danaher Corporation (DHR) Headed?Danaher Corporation (NYSE: DHR) , a global science and technology innovator, has recently been the subject of heightened investor attention following two significant announcements that collectively paint a picture of a company executing a disciplined capital allocation strategy. While rewarding shareholders with a consistent return of capital, Danaher is simultaneously making a bold, multi-billion dollar bet to solidify its leadership in the diagnostics space. These developments invite a closer examination of where the industrial and healthcare conglomerate is headed in the near and long term. Returning Value to Shareholders: The Quarterly Dividend First, in a move that underscores its commitment to providing tangible returns to its investors, Danaher announced on February 24 that its Board of Directors had approved a regular quarterly cash dividend of $0.40 per share of its common stock. This upcoming distribution is scheduled to be paid on April 24, 2026, to all shareholders of record as of the close of business on March 27, 2026. This declaration is consistent with Danaher's history as a reliable dividend payer. The company has established a track record of not only maintaining but steadily increasing its dividend over time, reflecting the strength of its diversified business model and its capacity to generate substantial, recurring free cash flow. For income-oriented investors, this regular payout provides a measure of stability and confidence, even as the company pursues larger strategic initiatives. A Transformative Acquisition: The $9.9 Billion Masimo Deal Just one week prior to the dividend announcement, on February 17, Danaher unveiled its most ambitious strategic move in recent memory: a definitive agreement to acquire Masimo Corporation. Masimo is widely recognized as a leading, specialized provider of innovative noninvasive patient monitoring technologies. The company is particularly renowned for its advanced pulse oximetry solutions, as well as a broader portfolio of patient monitoring devices and sensors, with its primary market focus being acute care settings such as hospitals and intensive care units. The financial terms of the agreement are substantial. Danaher will acquire all outstanding shares of Masimo common stock for $180 per share in cash. This translates to a total enterprise value of approximately $9.9 billion , a figure that includes the assumption of Masimo's existing indebtedness and is net of any acquired cash. From a valuation perspective, Danaher's management has provided context for the deal's financial logic. They stated that the acquisition price represents a transaction multiple of roughly 18 times Masimo's estimated EBITDA for the full year 2027. However, when incorporating the full run-rate impact of expected annual cost synergies—efficiencies gained by combining operations, leveraging scale, and integrating functions—the effective multiple compresses to a more attractive 15 times the estimated 2027 EBITDA. This suggests that management sees a clear and actionable path to extracting value from the combination, making the premium price justifiable. Strategic Integration and Portfolio Synergy A critical element of the deal's structure is how Masimo will be integrated into the existing Danaher ecosystem. Upon completion of the transaction, Masimo is slated to operate as a standalone operating company within Danaher's Diagnostics segment. It will join a formidable and highly complementary portfolio of diagnostics leaders, including: Radiometer: A leader in acute care diagnostics, particularly blood gas analysis. Leica Biosystems: A provider of comprehensive workflows and automation for cancer diagnostics. Cepheid: A pioneer in rapid molecular diagnostics for infectious diseases. Beckman Coulter Diagnostics: A broad-based provider of clinical chemistry, immunoassay, and hematology systems for laboratories. This placement is highly strategic. Masimo's strength in noninvasive patient monitoring at the bedside directly complements Radiometer's leadership in acute care diagnostics. Together, they can offer a more comprehensive suite of technologies to hospital systems, from continuous monitoring to critical lab results. This synergy is expected to enhance Danaher's value proposition to healthcare providers, particularly in the high-acuity hospital environment. The Growth Trajectory and Danaher's Core Business Looking ahead, Danaher’s leadership has expressed strong confidence in Masimo's organic growth potential. The company has stated that Masimo is anticipated to deliver high-single-digit core revenue growth over the long term. This projected performance is not just an isolated benefit; it is expected to be additive enough to accelerate the core revenue growth profile of Danaher's entire Diagnostics segment. This is a crucial point, as it indicates that the acquisition is not merely about adding scale, but about enhancing the overall growth trajectory of one of the company's primary operating pillars. To fully appreciate this move, one must understand Danaher's broader business architecture. The corporation designs, manufactures, and markets a wide array of professional, medical, industrial, and commercial products and services. It is organized into four primary operating segments: Diagnostics: As highlighted, this segment offers a comprehensive range of clinical instruments, devices, consumables, reagents, and services used by hospitals, laboratories, and physicians to diagnose and treat diseases and other medical conditions. Biotechnology: This segment provides a vast portfolio of equipment, consumables, and software that enable the research, development, and commercial production of biological medicines, including monoclonal antibodies and novel cell and gene therapies. Life Sciences: This segment offers an extensive suite of instruments and consumables used by researchers to study the fundamental biology of cells and molecules, accelerating the path to new discoveries. Environmental and Applied Solutions: This segment provides products and services that help protect critical water supplies and analyze and solve complex industrial and environmental challenges. Conclusion: A Dual-Pronged Strategy for Future Value In summary, Danaher Corporation (DHR) appears to be heading in a direction defined by a clear, dual-pronged strategy. On one hand, it maintains a disciplined approach to returning capital to shareholders through its reliable and growing quarterly dividend. On the other, it is aggressively deploying its balance sheet to acquire high-quality, high-growth assets like Masimo at a strategic price. By integrating Masimo into its Diagnostics segment, Danaher is not only adding a premier technology portfolio but is also positioning itself to capture greater share of the growing acute care and patient monitoring markets. For investors, the path ahead for Danaher looks to be one of continued portfolio optimization, synergistic growth, and a steadfast focus on its core mission of helping to realize the full potential of science and technology to improve human health.

Mean Reversion Setup: DHR 1. RSI in oversold region 2. Price likely to rebound back to the mean Trade Rules: Entry Trigger - RSI has cross below oversold region, enter limit buy at close price Exit Trigger - Close at market when close price cross above exit trigger (Red Line) Notes: Maximum of 3 open positions

DHR, Massive BULLISH Wedge-Formation, Major BREAKOUT Incoming!Hello There! Welcome to my new analysis of DHR. The stock market is in a really important condition currently as there are many interesting stock gems within the market I have spotted in my analytics backend. One of the interesting gems I recently spotted for a major opportunity on the long side of the market is DHR. This gem has major underlying potential to increase a huge breakout dynamic in the upcoming times. When looking at my chart now DHR is bouncing several times within the major ascending channel formation, this channel formation is a substantial origin of several support bounces from where DHR could increase with bullish momentum volatility. Now, DHR is bouncing within the range for the next consecutive time and is already marking the level as a main support from where the next main bullish expansion spike is likely to emerge. What is so important within this whole newly developed formational structure is that DHR is now also forming this momentous descending wedge-formation in which it already completed the coherent wave count especially bouncing within the lower boundary of the wedge and is now building up the further determinations. The fact that DHR already completed the wave count and bounced within the lower boundary is already nearly completing the whole descending wedge formation. With these main underlying confirmational developments, DHR is building a massive bullish base here. Putting this into perspective this means that DHR is likely to emerge with the final wedge-breakout within the next times which is going to form the completion-setup with the breakout above the boundary as marked in my chart. Once DHR has formed this completion-setup it is going to be the main origin of the bullish wave-expansion towards the upper directions and reaching the target zones with the wave-C extension. Thank you everybody for watching my idea about DHR. Support from your side is greatly appreciated. VP

DHR NYSE:DHR Q3 2025 Report HIGHLIGHTS EPS: $1.89, approximately 10% above the consensus estimate of $1.72 Biotechnology Segment: Grew 8.8% year-on-year, continuing its streak of quarterly growth Financials: Free cash flow for the quarter was $1.4 billion, with the operating profit margin increasing 40 basis points year-on-year to 27.9% Share Repurchase: The company repurchased 10 million shares for $2.01 billion. In September 2025, a new share repurchase program of up to 35 million shares was approved by the Board 2026 Guidance: Management provided its first guidance for 2026, expecting core revenue growth in the range of 3-6% and EPS growth. KEY DRIVERS 🔎

by A3MInvestments

DHR - deteriorating health signals ======= Volume ======= -slight decrease -stable ========== Price Action ========== - Bearish flag formed both long and short term ========= Oscillators ========= - Ichimoku, all lines under red expanding kumo - MACD turning down - DMI Neutral - StochRSI turning down, showing bearish signals ========= Conclusion ========= - Long term swing, price may reverse, to enter spot or wait for pullback.

Mean Reversion Setup: DHR 1. RSI in oversold region 2. Price likely to rebound back the the mean Trade Rules: Entry Trigger - RSI has cross below oversold region, enter limit buy at close price Exit Trigger - Close at market when close price cross above exit trigger (Red Line)

Mean Reversion Setup: DHR 1. RSI in oversold region 2. Price likely to rebound back the the mean Trade Rules: Entry Trigger - RSI has cross below oversold region, enter limit buy at close price Exit Trigger - Close at market when close price cross above exit trigger (Red Line)

DHR: Bullish Breakout from Descending Trendline Overview: Danaher Corporation (DHR) on the daily chart appears to have undergone a significant bearish pattern followed by a period of consolidation. The recent price action suggests a potential bullish reversal, as the stock has now broken above a key descending trendline, signaling a shift in momentum. Context & Price History: Prior Topping Pattern: From roughly February to April, DHR exhibited classic signs of a topping formation. The price repeatedly failed to break above the 210 to 215 Resistance zone (red shaded area), indicating strong supply in this region. The price action leading to the sharp April decline could be interpreted as a Head and Shoulders pattern or a triple top, with the white horizontal line around 196- 197 acting as a critical "neckline" or support level. Sharp Decline & Key Support: Following the breakdown from the neckline in April, DHR experienced a significant sell-off, finding strong demand and bottoming out within the 180 to 185 Key Level support zone (green shaded area). This zone has proven to be a robust area of buyer interest. Consolidation & Descending Trend: Since the April lows, DHR has been trading within a range, largely constrained by a descending trendline (thick red diagonal line) acting as dynamic resistance, while finding support at the 180-185 key level. This price action formed a descending triangle or wedge-like pattern. Key Levels & Patterns: Major Resistance (210 to 215): A strong supply zone where sellers have repeatedly stepped in. This will be the primary upside target if the current bullish momentum sustains. Key Support (180 to 185): A critical demand zone that has held up well, providing a strong foundation for the recent recovery. Descending Trendline (Red): This dynamic resistance has capped rallies since March/April. A decisive break above it is a bullish signal. Pivotal Level (~196-197, White Line): This level acted as prior support (neckline) before the April drop. Now, it serves as a minor horizontal resistance that the price has recently overcome, potentially flipping to support on a retest. Current Situation (As of Analysis): DHR is currently trading around $200. Critically, the price has made a strong move above the long-standing descending trendline. This breakout suggests that bullish sentiment is gaining control after a prolonged period of consolidation. Potential Scenarios: Bullish Continuation (Primary Indication on Chart): Confirmation: The chart's projection anticipates a retest of the broken descending trendline (which now acts as support) or the ~ 196=197 pivotal level, followed by a bounce and continuation higher. First Target: Upon a successful retest and bounce, the immediate target for buyers would be the 210 to 215 Resistance zone. Why: A confirmed breakout from a multi-month descending trendline, especially after holding strong key support, is a strong bullish reversal signal. Bearish Rejection / Fakeout: Confirmation: If DHR fails to hold above the broken descending trendline and closes convincingly back below it (and potentially below the ~196-197 level), it would suggest that the breakout was a "fakeout." Downside Potential: In such a scenario, the price could re-enter the consolidation range and potentially retest the 180 to 185 Key Level. Confirmation & Invalidations: Bullish Confirmation: A successful retest of the descending trendline (now support) with a clear bounce, or a sustained daily close above the ~196-197 level, preferably with increasing volume. Invalidation of Bullish Setup: A decisive daily close back below the descending trendline and the ~ 196-197 pivotal level would suggest that the bullish momentum has faltered and the current breakout might be false. Conclusion: DHR has presented a compelling technical setup with a breakout from a significant descending trendline. This breakout, combined with the stock holding firm at the 180-185 key support, suggests a potential shift in trend from bearish consolidation to a renewed bullish advance. Traders should look for confirmation of the breakout (e.g., a successful retest and bounce) before targeting the 210-215 resistance zone. Disclaimer: The information provided in this chart is for educational and informational purposes only and should not be considered as investment advice. Trading and investing involve substantial risk and are not suitable for every investor. You should carefully consider your financial situation and consult with a financial advisor before making any investment decisions. The creator of this chart does not guarantee any specific outcome or profit and is not responsible for any losses incurred as a result of using this information. Past performance is not indicative of future results. Use this information at your own risk. This chart has been created for my own improvement in Trading and Investment Analysis. Please do your own analysis before any investments.

Multiple Low We are close to the price low since 2020 now. This may seen as an important support. But the momentumis still high enough so that it may take time to build a bottom here. Before a major attempt to correct upward the lows at around 190 will likely be tested.

Bottom Building For weeks we are testing this level now but cannot break it. Due to the large drop since January I consider a corrective rise as more likely now.

Correction Retraced Supposed to have found the bottom at 195.50 for now it may be time to resume the upward correction after this 50 % downward retracement. There is an open window to be closed at 222.37.

Overbought and Double Top on 1h chart.Target 1 $207.92 Target 2 $204 Enter at open Monday 3.10.25 3.-14 Puts stk 207.50 $1.65/contract

Higher Highs for Danaher Corp. DHR ABC zigzag complete, now out of OBOS territory and MIDAS curve crossed. vWAP is supportive. BB%PCT crossed zero line and growing, VZO ribbon cross noted as well. One higer low established also. Let's go!

by Rykin_Capital

Still the Split The extended split that the market has done 2-3 days ago has not yet been digested. The window has to be closed. When it becomes cold and you sit in a split ypo will get cramps definitely. I mean it would be healthy for the market to correct the steep fall and to close the window. Today will be decisive to learn whether the market is ready to build a bottom here. I think so as the market seems to be exhausted.

The Splits A fall fromthe high tothe present low within less than 2 days is a real split. Nobody can very long hold such a position without getting a cramp. Thus the spilit shall be closed to a normal position again, i.e. the market will take profit.

$DHR with a neutral outlook following its earnings #Stocks The PEAD projected a neutral outlook for NYSE:DHR after a negative under reaction following its earnings release placing the stock in drift D with an expected accuracy of 57.14%.

Long $DHR off AVWAP and 200DMA Entry $248.84 SL below recent LVN in volume profile $247.13 TP at LVN in 60m TF $258.5 Possibly more room to run above that as well.

Danaher,,, pullback Uptrend Trading on the pullbacks is one of the best strategies. I see a good pullback to the broken level after transferring between bulls and bears at the S/R zone. As a trigger for entry, there is a good bullish candle but i will not enter until about 15min before bell to remain this candle in a good shape without up shadow. SL and TP are clarified on the chart.

DHR at bottom channel DHR at bottom channel Oversold Gap closure Upside target $254

by chancethepug

(New Trade) DHR Disclaimer: All information posted are the author's own trades/potential trades. The author is not a certified Financial Advisor and do not have the certifications to provide financial advice. These information are strictly for educational purposes only and do not constitute any financial, investment or trading advice of any form. Please do your own research (DYOR) before taking any investment/trading actions. The author will not be liable for any legal liabilities or responsibilities due to actions taken by any reader of these postings. Counter has broken a downtrend trendline which spanned more than 2 years in Jan 2024 Since its Oct 2023 lows, prices have rallied impulsively in 5 waves and retraced to its near term Apr 2024 lows which could act as support to allow counter to push up higher in Minuette Wave (iii) Opened a new position into as a Breakout Trade Entry: $256.72 Initial S/L: $ 230.74

by ElliotWaveTrades